TABLE 1.
Patients with whole-genome sequencing predicted bedaquiline (BDQ)-resistant Mycobacterium tuberculosis complex isolates in the Republic of Moldova between 2016 and 2018
| Patient (isolate ID), sampling time | Rv0678 (mutation frequency %) | atpE (mutation frequency %) | BDQ MIC MGIT 960 (mg·mL−1) | CFZ MIC MGIT 960 (mg·mL−1) |
| Patient 29 (CAR-13), prior to BDQ | Wild-type | Wild-type | ≤0.5 (S) | ≤0.5 (S) |
| Patient 29 (CAR-38), after BDQ, acquired resistance | Wild-type | I66M# (97%) | >2.0 | ≤0.5 (S) |
| Patient 12 (CAR-52), prior to BDQ | Wild-type | Wild-type | ≤0.5 (S) | ≤0.5 (S) |
| Patient 12 (CAR-61) after BDQ, acquired resistance | 16_del_g (57.4%) 193_del_g# (12.7%) G24D (19.8%) |
Wild-type | 2.0 | 1.0 (S) |
| Patient 2 (CAR-78), prior to BDQ | Wild-type | Wild-type | ≤0.5 (S) | ≤0.5 (S) |
| Patient 2 (CAR-87), after BDQ, acquired resistance | 192insG# (2%) | A63P# (25%) | >2.0 (R) | 2.0 (R) |
| Patient 37 (CAR-10), prior to BDQ | Wild-type | Wild-type | ≤0.5 (S) | ≤0.5 (S) |
| Patient 37 (CAR-18), after BDQ, re-infection | T58P (100%) | Wild-type | 2.0 (R) | 1.0 (S) |
| Patient 57 (CAR-45), prior to BDQ | Wild-type | Wild-type | ≤0.5 (S) | ≤0.5 (S) |
| Patient 57 (CAR-55), after BDQ, acquired resistance | 193_del_g# (44.4%) S63G# (5.5%) |
E61D# (27.5) I66M# (2.6%) |
>2.0 (R) | 1.0 (S) |
| Patient 32 (CAR-84), after BDQ | 192_ins_g# (74.2%) 193_del_g# (5.7%) |
Wild-type | 1.0 (S) | 1.0 (S) |
| Patient 71 (CAR-40), after BDQ | 192ins_g# (23.8%) L142P (64%) |
Wild-type | >2.0 (R) | 2.0 (R) |
| Patient 61 (CAR-1), after BDQ | 136_ins_g (7.1%) 141_ins_c# (69.0%) 195_ins_t# (5.8%) G66W (6.0%) |
Wild-type | >2.0 (R) | 2.0 (R) |
| Patient 33 (CAR-43), after BDQ | 436_ins_t (90.2%) R72W (28.5%) |
Wild-type | >2.0 (R) | >2.0 (R) |
MIC: minimum inhibitory concentration; CFZ: clofazimine; S: susceptible; R: resistant. #: mutation reviewed in [33].